Chemical Information
Antiviral agent ID	DrugRepV_4404
Antiviral agent name	N-(3-pyridinylmethyl)dibenzo[b,d]furan-3-amine
IUPAC Name	N-(3-pyridinylmethyl)dibenzo[b,d]furan-3-amine
SMILES (canonical)	C1=CC=C2C(=C1)C3=C(O2)C=C(C=C3)NCC4=CN=CC=C4
Molecular Formula	C18H14N2O
Molecular Weight (g/mol)	274.3
InChl	InChI=1S/C18H14N2O/c1-2-6-17-15(5-1)16-8-7-14(10-18(16)21-17)20-12-13-4-3-9-19-11-13/h1-11,20H,12H2
Structural Information
Clinical Information
Biological Information
Secondary Indication	Hendra virus (HeV) NA F0, amino acids 105 to 114
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	In-vitro
Secondary Indication (Model system) [cell lines/ animal models]	293FT
Secondary Indication (Viral titer)	1 μM
Secondary Indication (Mode of drug delivery)	Culture
Secondary Indication (Drug concentration)	40 μM
Secondary Indication (Cell based assay)	CatL-Peptide cleavage
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	Percentage inhibition [ 21.93 % ]
Reference	Elshabrawy HA, Fan J, Haddad CS, Ratia K, Broder CC, Caffrey M, Prabhakar BS..Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay..J Virol. 2014 Apr;88(8):4353-65. doi: 10.1128/JVI.03050-13. Epub 2014 Feb 5. PubMed Central PMCID: P PMID:24501399
Comment	A novel broad-spectrum small molecule that could block cathepsin L-mediated cleavage was identified and thus inhibit the entry of pseudotypes bearing the glycoprotein derived from SARS-CoV or Ebola, Hendra, or Nipah virus. The small molecule can be further optimized and developed into a potent broad-spectrum antiviral drug.